Sodium-dependent glucose transporter 2 as a diagnostic and therapeutic target for pre-malignant lesions

Abstract

Methods, kits, and compositions are described for the detection and treatment of premalignant lesions. This early detection allows patients to avoid the risks associated with repetitive imaging often employed to seek differentiation between developing cancer and inflammation. The method comprises (a) administering to the subject a radiographic tracer for a sodium/glucose cotransporter (SGLT): (b) performing a radiographic detection scan of the subject; and (c) detecting signal emitted by the tracer taken up in the scanned subject, whereby detected signal in the subject is indicative of a pre-malignant lesion. In some embodiments, the method further comprises administering an inhibitor of sodium-glucose transporter 2 (SGLT2), such as gliflozin, to a subject in whom a pre-malignant lesion has been detected. In some embodiments, the pre-malignant lesion is in tissue that expresses SGLT2, such as a lung, prostate, bladder, breast, or pancreatic lesion.

Dependencies are inferred from the claim text.